Mutagenic Impurities: Precompetitive/Competitive Collaborative and Data Sharing Initiatives
暂无分享,去创建一个
Angela White | Andrew Teasdale | Elizabeth M. Covey-Crump | David P. Elder | James Harvey | Richard Vaughan Williams | R. Williams | D. Elder | A. Teasdale | J. Harvey | E. Covey-Crump | Angela White
[1] D. Elder,et al. An Approach to Control Strategies for Sulfonate Ester Formation in Pharmaceutical Manufacturing Based on Recent Scientific Understanding , 2012 .
[2] David Q. Liu,et al. A practical derivatization LC/MS approach for determination of trace level alkyl sulfonates and dialkyl sulfates genotoxic impurities in drug substances. , 2008, Journal of pharmaceutical and biomedical analysis.
[3] David S. Jones. The Journal of Pharmacy and Pharmacology 2008 , 2009 .
[4] Jared L. Anderson,et al. Determination of trace level genotoxic impurities in small molecule drug substances using conventional headspace gas chromatography with contemporary ionic liquid diluents and electron capture detection. , 2014, Journal of chromatography. A.
[5] Heather Scott,et al. Ames positive boronic acids are not all eukaryotic genotoxins. , 2015, Mutation research. Genetic toxicology and environmental mutagenesis.
[6] William F. Kiesman,et al. Case Studies in the Applicability of Drug Substance Design Spaces Developed on the Laboratory Scale to Commercial Manufacturing , 2015 .
[7] Patrick Sandra,et al. A Detailed Study of Sulfonate Ester Formation and Solvolysis Reaction Rates and Application toward Establishing Sulfonate Ester Control in Pharmaceutical Manufacturing Processes , 2010 .
[8] D. Elder,et al. Analytical approaches for the detection of epoxides and hydroperoxides in active pharmaceutical ingredients, drug products and herbals. , 2010, Journal of pharmaceutical and biomedical analysis.
[9] Karen M. Alsante,et al. In silico prediction of pharmaceutical degradation pathways: a benchmarking study. , 2014, Molecular pharmaceutics.
[10] V. Ciaravino,et al. An assessment of the genetic toxicology of novel boron‐containing therapeutic agents , 2013, Environmental and molecular mutagenesis.
[11] H. Niederländer,et al. A new derivatization reagent for LC-MS/MS screening of potential genotoxic alkylation compounds. , 2013, Journal of pharmaceutical and biomedical analysis.
[12] Achille Cappiello,et al. A new liquid chromatography-mass spectrometry approach for generic screening and quantitation of potential genotoxic alkylation compounds without derivatization. , 2012, Journal of chromatography. A.
[13] D. Elder,et al. Control and analysis of alkyl esters of alkyl and aryl sulfonic acids in novel active pharmaceutical ingredients (APIs). , 2008, Journal of pharmaceutical and biomedical analysis.
[14] Nigel Greene,et al. In silico methods combined with expert knowledge rule out mutagenic potential of pharmaceutical impurities: an industry survey. , 2012, Regulatory toxicology and pharmacology : RTP.
[15] David H Phillips,et al. Boronic acids-a novel class of bacterial mutagen. , 2011, Mutation research.
[16] Andrew Teasdale,et al. A Tool for the Semiquantitative Assessment of Potentially Genotoxic Impurity (PGI) Carryover into API Using Physicochemical Parameters and Process Conditions , 2010 .
[17] D. Elder,et al. Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs). , 2008, Journal of pharmaceutical and biomedical analysis.
[18] Scott Boyer,et al. Use of in silico systems and expert knowledge for structure-based assessment of potentially mutagenic impurities. , 2013, Regulatory toxicology and pharmacology : RTP.
[19] J. Woodcock. Precompetitive Research: A New Prescription for Drug Development? , 2010, Clinical pharmacology and therapeutics.
[20] Andrei Medvedovici,et al. Assay at low ppm level of dimethyl sulfate in starting materials for API synthesis using derivatization in ionic liquid media and LC-MS. , 2013, Journal of pharmaceutical and biomedical analysis.
[21] David Q. Liu,et al. A generic approach for the determination of trace hydrazine in drug substances using in situ derivatization-headspace GC-MS. , 2009, Journal of pharmaceutical and biomedical analysis.
[22] Andrew Teasdale,et al. Risk Assessment of Genotoxic Impurities in New Chemical Entities: Strategies To Demonstrate Control , 2013 .
[23] D. Elder,et al. Control and analysis of hydrazine, hydrazides and hydrazones--genotoxic impurities in active pharmaceutical ingredients (APIs) and drug products. , 2011, Journal of pharmaceutical and biomedical analysis.
[24] David Q. Liu,et al. Recent advances in trace analysis of pharmaceutical genotoxic impurities. , 2010, Journal of pharmaceutical and biomedical analysis.
[25] Feng Zheng,et al. Rapid and simultaneous determination of sulfonate ester genotoxic impurities in drug substance by liquid chromatography coupled to tandem mass spectrometry: comparison of different ionization modes. , 2014, Journal of chromatography. A.
[26] N V V S S Raman,et al. Strategies for the identification, control and determination of genotoxic impurities in drug substances: a pharmaceutical industry perspective. , 2011, Journal of pharmaceutical and biomedical analysis.
[27] G. Sluggett,et al. Determination and control of TEMPO, a potentially genotoxic free radical reagent used in the synthesis of filibuvir. , 2012, Journal of pharmaceutical and biomedical analysis.
[28] Patrick Sandra,et al. The utility of sulfonate salts in drug development. , 2010, Journal of pharmaceutical sciences.
[29] Christopher J. Welch,et al. Precompetitive Collaboration on Enabling Technologies for the Pharmaceutical Industry , 2014 .
[30] Patrick Sandra,et al. Mechanism and Processing Parameters Affecting the Formation of Methyl Methanesulfonate from Methanol and Methanesulfonic Acid: An Illustrative Example for Sulfonate Ester Impurity Formation , 2009 .
[31] M. A. Ott,et al. An expert system to predict the forced degradation of organic molecules. , 2013, Molecular pharmaceutics.
[32] R. E. Boyle. THE REACTION OF DIMETHYLSULFOXIDE AND 5-DIMETHYL AMINONAPHTHALENE-1- SULFONYL CHLORIDE , 1966 .
[33] Thomas E. Exner,et al. Can quantum-chemical NMR chemical shifts be used as criterion for force-field development , 2014, Journal of Cheminformatics.
[34] P R Kakadiya,et al. Low level determinations of methyl methanesulfonate and ethyl methanesulfonate impurities in Lopinavir and Ritonavir Active pharmaceutical ingredients by LC/MS/MS using electrospray ionization. , 2011, Journal of pharmaceutical and biomedical analysis.
[35] D. Elder,et al. Drug substances presented as sulfonic acid salts: overview of utility, safety and regulation , 2009 .
[36] Roman Szucs,et al. A generic approach for the determination of residues of alkylating agents in active pharmaceutical ingredients by in situ derivatization-headspace-gas chromatography-mass spectrometry. , 2007, Journal of pharmaceutical and biomedical analysis.
[37] Andrew Teasdale,et al. Development and validation of an automated static headspace gas chromatography-mass spectrometry (SHS-GC-MS) method for monitoring the formation of ethyl methane sulfonate from ethanol and methane sulfonic acid. , 2008, Journal of pharmaceutical and biomedical analysis.
[38] Samuel J. Webb,et al. Self organising hypothesis networks: a new approach for representing and structuring SAR knowledge , 2014, Journal of Cheminformatics.
[39] G. Szekely,et al. Design of experiments as a tool for LC-MS/MS method development for the trace analysis of the potentially genotoxic 4-dimethylaminopyridine impurity in glucocorticoids. , 2012, Journal of pharmaceutical and biomedical analysis.
[40] T. Singer,et al. Comparative evaluation of in silico systems for ames test mutagenicity prediction: scope and limitations. , 2011, Chemical research in toxicology.
[41] Carol A Marchant,et al. In Silico Tools for Sharing Data and Knowledge on Toxicity and Metabolism: Derek for Windows, Meteor, and Vitic , 2008, Toxicology mechanisms and methods.